To provide delegates with increased awareness of Type 2 Diabetes as a Cardiovascular (CV) Disease;assessing CV risk; reviewing current glucose lowering therapies and interventions and consideringtools that may help convey to patient both CV risk and benefits of intervention.We will review the most recent evidence around our currently available glucose lowering therapiesin respect of CV profile and consider benefits of individualised and combination therapies tooptimise patient outcomes.Learning OutcomesFollowing this session, delegates will be able to: Describe a clearer understanding of current glucose lowering therapies, pro’s and con’s of each therapy and increased awareness of and confidence in decision making around the next most appropriate intervention. Detail the latest evidence supporting glucose lowering therapy use, particularly in respect of CV profile. Consider the potential benefit of composite CV endpoints and targeting in diabetes. More confidently present patients with appropriate treatment options for glucose lowering. Employ a range of behavioural, motivational strategies that may help patients arrive at a helpful risk / benefit appraisal and be more willing to accept intervention.Clinical OutcomesIt is anticipated that that following this session, delegates will achieve: Be better able to discuss with patients, the vascular nature of their diabetes, risk and benefits of intervention. By appropriate use of glucose lowering and other CV protective agents, to help achieve composite CV targets and so improve patient cardiovascular outcomes.